EGRIFTA® is a registered trademark of Theratechnologies Inc.
© 2011 EMD Serono, Inc. All rights reserved.

Understanding HIV-Related Excess Belly Fat

What Is HIV-Related Excess Belly Fat?

People with HIV may have fat that builds up in some places and goes away in others. This is called “lipodystrophy” (lie-poh-DIS-tro-fee).

Some people with HIV who have lipodystrophy can develop excess belly fat. This is a type of lipodystrophy called abdominal “lipohypertrophy” (lie-poh-hi-PER-tro-fee). The excess belly fat is called “visceral adipose tissue” (VAT).

VAT is:

  • Hard fat that surrounds a person’s abdominal organs
  • Chronic (meaning it lasts a long time)
  • May not go away with diet and exercise alone

Who Is at Risk?

It’s important to remember that gaining this excess VAT is not typical. When most people without HIV gain weight in their belly, they usually gain some VAT, but they gain more ‘soft’ fat just under the surface of the skin.

People with HIV can gain excess VAT in their belly and may actually lose the soft fat in their belly and other parts of their body. Healthcare providers and scientists are not sure about how the excess VAT develops in people living with HIV.

There are a variety of factors that may increase the risk of someone who is HIV+ developing HIV-related abdominal lipohypertrophy, or excess belly fat, including:

  • Age. People over the age of 40 have a higher chance of being diagnosed with HIV-related abdominal lipohypertrophy
  • Length of infection. Those who have had HIV for more than three years are at an increased risk
  • Markers of disease severity. If your lowest CD4 count is below 100, you may be at risk. This may be related to the effect HIV has on different types of cells in the body. HIV can change the way those cells normally work
  • Use and duration of ART. Some types of antiretroviral therapy (ART), specifically protease inhibitors, are believed to play a role in HIV-related abdominal lipohypertrophy. Although not completely understood, the condition may be related to direct effects of the medications or to the viral suppression that happens as a result of taking the medications
  • Ethnicity. Non-Caucasians are more likely to develop HIV-related abdominal lipohypertrophy
  • Gender. Women are at a greater risk than men, although because there are more men with HIV in the US, there are likely more men with the condition. However, a woman with HIV may be more likely than a man to develop HIV-related abdominal lipohypertrophy
  • Lifestyle factors. Smoking and/or having a higher body mass index (BMI) (higher than 26) have been shown to influence the condition. To learn more about BMI and calculate your own, visit the Centers for Disease Control and Prevention here

Identifying HIV-Related Excess Belly Fat (Abdominal Lipohypertrophy)

While the medical community has not yet standardized the way HIV-related abdominal lipohypertrophy is identified, there are a few common methods doctors use, including:

  • Measurements of different body parts, including the size of your waist and hips
  • Patient questionnaires
  • Physical exams
  • Assessment of the type of body fat

If you think you may have HIV-related abdominal lipohypertrophy, you should talk to your doctor. Use the Doctor Discussion Guide to help start the conversation.

Important Risk Information and Indication for EGRIFTA®

EGRIFTA® (eh-GRIF-tuh)
(tesamorelin for injection) for subcutaneous use

Do not use EGRIFTA® if you:
  • have pituitary gland tumor, pituitary gland surgery or other problems related to your pituitary gland
  • have or had a history of active cancer (either newly diagnosed or recurrent)
  • are allergic to tesamorelin or any of the ingredients in EGRIFTA® (mannitol or sterile water)
  • are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA® and talk with your healthcare provider.
Before using EGRIFTA®, tell your healthcare provider if you:
  • have or have had cancer
  • have diabetes
  • are breastfeeding or plan to breastfeed. It is not known if EGRIFTA® passes into your breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers not breastfeed to avoid the risk of passing HIV infection to your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking EGRIFTA®
  • have kidney or liver problems
  • have any other medical condition.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. EGRIFTA® may affect the way other medicines work, and other medicines may affect how EGRIFTA® works.

How should I use EGRIFTA®?
  • Read the detailed "Instructions for Use" that comes with EGRIFTA® before you start using EGRIFTA®. Your healthcare provider will show you how to inject EGRIFTA®.
  • Use EGRIFTA® exactly as prescribed by your healthcare provider.
  • Inject EGRIFTA® under the skin (subcutaneously) of your stomach area (abdomen).
  • Change (rotate) the injection site on your stomach area (abdomen) with each dose. Do not inject EGRIFTA® into scar tissue, bruises or your navel.
  • Do not share needles or syringes with other people. Sharing of needles can result in the transmission of infectious diseases, such as HIV.
EGRIFTA® may cause serious side effects including:
  • Serious allergic reaction. Some people taking EGRIFTA® may have an allergic reaction.

    Stop using EGRIFTA® and get emergency help right away if you have any of the following symptoms:
    • a rash over your body
    • hives
    • swelling of your face or throat
    • shortness of breath or trouble breathing
    • fast heartbeat
    • feeling of faintness or fainting
  • Swelling (fluid retention). EGRIFTA® can cause swelling in some parts of your body. Call your healthcare provider if you have an increase in joint pain, or pain or numbness in your hands or wrist (carpal tunnel syndrome).
  • Increase in glucose (blood sugar) intolerance and diabetes. Your healthcare provider will measure your blood sugar periodically.
  • Injection site reactions. Change (rotate) your injection site to help lower your risk for injection site reactions. Call your healthcare provider for medical advice if you have the following symptoms around the area of the injection site:
    • redness
    • itching
    • pain
    • irritation
    • bleeding
    • rash
    • swelling
The most common side effects of EGRIFTA® include:
  • joint pain
  • pain in legs and arms
  • swelling in your legs
  • muscle soreness
  • tingling, numbness and pricking
  • nausea
  • vomiting
  • rash
  • itching

These are not all the possible side effects of EGRIFTA®. For more information, ask your healthcare provider or pharmacist.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. To report side effects, contact EMD Serono toll-free at 1-800-283-8088 ext. 5563. You may report side effects to FDA at 1-800-FDA-1088.

Use:
  • EGRIFTA® is an injectable prescription medicine to reduce the excess in abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA® contains a growth hormone-releasing factor (GRF).
  • The impact and safety of EGRIFTA® on cardiovascular health has not been studied.
  • EGRIFTA® is not indicated for weight loss management.
  • It is not known whether taking EGRIFTA® helps improve compliance with anti-retroviral medications.
  • It is not known if EGRIFTA® is safe and effective in children. EGRIFTA® is not recommended to be used in children.

If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about EGRIFTA® that is written for healthcare professionals.

For more information about EGRIFTA®, contact the AXIS Center toll-free at 1-877-714-AXIS(2947).

Close x